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Peta Tunicliff, RN,1 Patricia M. Davidson, RN, PhD,2,8 and Peter S. Macdonald, MD, PhD1,5,6Background.We recently reported that frailty is independently predictive of increased mortality in patients with advanced heart
failure referred for heart transplantation (HTx). The aim of this studywas to assess the impact of frailty on short-term outcomes after
bridge-to-transplant ventricular assist device (BTT-VAD) implantation and/or HTx and to determine if frailty is reversible after these
procedures.Methods.Between August 2013 and August 2016, 100 of 126 consecutive patients underwent frailty assessment
using Fried’s Frailty Phenotype before surgical intervention: 40 (21 nonfrail, 19 frail) BTT-VAD and 77 (60 nonfrail, 17 frail) HTx—
including 17 of the 40 BTT-VAD supported patients. Postprocedural survival, intubation time, intensive care unit, and hospital
length of stay were compared between frail and nonfrail groups. Twenty-six frail patients were reassessed at 2 months or longer
postintervention. Results. Frail patients had lower survival (63 ± 10% vs 94 ± 3% at 1 year, P = 0.012) and experienced signif-
icantly longer intensive care unit (11 vs 5 days, P = 0.002) and hospital (49 vs 25 days, P = 0.003) length of stay after surgical in-
tervention compared with nonfrail patients. Twelve of 13 frail patients improved their frailty score after VAD (4.0 ± 0.8 to 1.4 ± 1.1,
P < 0.001) and 12 of 13 frail patients improved their frailty score after HTx (3.2 ± 0.4 to 0.9 ± 0.9,P < 0.001). Handgrip strength and
depression improved postintervention. Only a slight improvement in cognitive functionwas seen postintervention.Conclusions.
Frail patients with advanced heart failure experience increased mortality and morbidity after surgical intervention with BTT-VAD or
HTx. Among those who survive frailty is partly or completely reversible underscoring the importance of considering this factor as a
dynamic not fixed entity.
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2 Transplantation DIRECT ■ 2017 www.transplantationdirect.comFrailty has recently been identified as an important con-sideration in the assessment of patients referred for heart
transplantation (HTx).1 Although previously considered
synonymous with advancing age, frailty is commonly identi-
fied among patients with advanced heart failure (AHF)
across all ages. Several studies have identified that frailty pro-
vides a simple and effective means of risk stratification in pa-
tients undergoing cardiac surgical interventions,2 including
younger heart transplant patients.3 In our previous studies
of frailty in patients referred for HTx, frailty was reflective
of increased vulnerability and was associated with an in-
creased waitlist mortality and adverse postinterventional
outcomes.3,4
In light of the growing body of evidence highlighting the
risks associated with being frail, and the ageing demographic
of patients being referred for and undergoing transplanta-
tion,5 Indeed, the 2016 ISHLT listing criteria recommended
that all patients undergoing transplant referral be assessed
for frailty1 in response to the growing body of evidence
highlighting the risks associated with facility and the ageing
demographic of patients being referred for and undergoing
transplantation.5
Although frail patients may face increased morbidity and
mortality risks from interventions, such as ventricular assist
device (VAD) implantation and/or HTx, these interventions
also have the potential to improve frailty severity. It has been
hypothesized that the key to differentiating between patients
who have positive and negative postinterventional outcomes
in of a patient’s frailty syndrome may lie in determining
whether their frailty is predominantly cardiovascular or
noncardiovascular in nature).6
Although there has yet to be any reports on the revers-
ibility of physical frailty in patients undergoing bridge-to-
transplant VAD (BTT-VAD) implantation or HTx, it is
known that there is significant improvement in several fac-
tors associated with being frail (including cardiac cachexia
and handgrip strength [HGS]) with these surgical inter-
ventions.7,8 Given the high prevalence of frailty among
those with AHF, the question of whether this syndrome
is reversed after surgical intervention is of considerable
clinical interest. The aims of this study were to assess the
impact of frailty on short-term outcomes after BTT-VAD
implantation and/or HTx and to determine if frailty, de-
pression, and cognitive impairment are reversible after
these procedures.TABLE 1.
The 5 domains of physical frailty with a possible score of 0 or 1 f
Modified version of Fried’s Frailty Phenotype
Domain
Exhaustion “In the last week, did you feel on at least 3 days, that everything yo
least 3 days, that you could not get going?” a response of “yes”
Grip strength Grip strength was considered weak if the average of 3 consecutive
deviations of sex and age adjusted normative values
Mobility Walking speed was considered slow if the average of 3 attempts to
Appetite “Have you, in the last 3 months, been eating more/less than usual?
Physical activity “How often do you engage in activities that require a low or modera
A response of “1 to 3 times a month or hardly ever” was classifMATERIALS AND METHODS
Study Population
Patients for this study were recruited between August 1,
2013, and August 31, 2016. During that period, 126 consec-
utive patients underwent major surgical intervention for
AHF at our institution—either BTT-VAD (n = 45) or HTx
(n = 81). Seventeen of the 45 BTT-VAD patients proceeded
to HTx during the same period, bringing the total number
of HTx to 98. The study population of 100 patients who
underwent frailty assessment before surgical intervention
comprised 40 BTT-VAD (17 proceeded to HTx) and 60
HTx without prior VAD support. Of the 26 patients ex-
cluded from the study, 7 were already on VAD support
before commencement of routine frailty testing in our ins-
titution and 19 were Intermacs class I and not able to be
assessed. Twenty-six patients, who were frail preintervention,
underwent repeat frailty assessment postintervention. This
study was reviewed and approved by the hospital’s research
ethics committee (reference number LNR/13/SVH/21). In-
formed consent was obtained from all patients for their data
to be entered prospectively into a dedicated database for sub-
sequent analysis.Frailty, Cognition, and Depression Assessment
Frailty was assessed using an adapted version of Fried’s
Frailty Phenotype. A detailed description of the assessment
tool has been described previously3 and are briefly outlined
in Table 1. The 5 functional domains assessed were exhaus-
tion, slowness, weakness, physical inactivity, and loss of ap-
petite. Patients who were unable to mobilize out of bed or a
chair at the time of assessment scored a point for slowness.
A score of 3 or higher over 5 was classified as frailty. Cogni-
tive impairment was assessed using the Montreal Cognitive
Assessment (MoCA) questionnaire,9 with scores less than
26 classified as cognitive impairment. The Depression in
Medical Illnesses (DMI-10)10 questionnaire was used to as-
sess depression, with scores of 9 or higher classified as de-
pression. Rationale for the use of the MoCA and DMI is
given in our previous study. Briefly, the MoCA has a good
sensitivity for the detection of mild levels of cardiac index
(CI) in HF patients, and the DMI tool circumvents depressive
elements (such as appetite and fatigue) which overlap with
frailty elements.4or each domain
u did was an effort?” and “In the last week, did you feel on at
to either question met the criteria for exhaustion
/5
attempts on the left and right hand fell below 2 standard
ok 6 seconds or more to complete 5 meters
” A response of “less” was classified as poor appetite
te level of energy, such as gardening, cleaning the car or going for a walk?”
ied as physical inactivity
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Reduced HGS—1 of the 5 items recorded during the full
frailty assessment—has been proposed as a single-item surro-
gate measure of frailty.8 HGS was assessed using a Jamar
Hand Dynamometer. Grip strength was considered weak if
the average of 3 consecutive attempts on the left and right
hand was less than 2 standard deviations below the sex-
and age-adjusted normative values. The higher of the right-
hand and left-hand averages were recorded for baseline and
follow-up HGS.
Assessment of Heart Failure Severity
As part of routine patient data collection, markers of heart
failure severity were also obtained. These includedNewYork
Heart Association (NYHA) class, heart failure duration, left
ventricular end-diastolic diameter (LVEDD) and left ventric-
ular ejection fraction (LVEF) by echocardiography, central
hemodynamic pressures including right atrial pressure (RAP),
mean pulmonary artery pressure (MPAP) and pulmonary ar-
tery wedge pressure (PAWP) and CI by right heart catheterisa-
tion. Patients were also stratified by LVEF into those with
heart failure and preserved ejection fraction (LVEF ≥ 40%
heart failure with a reduced ejection fraction [HFPEF]) and
those with heart failure and reduced ejection fraction
(LVEF < 40%, HFREF). Estimated glomerular filtration rate
(eGFR), calculated using the Modification of Diet in Renal
Disease formula, serum creatinine, bilirubin and albumin,
blood hemoglobin levels and body mass index (BMI) (calcu-
lated as weight/height2 (kg/m2), were also recorded.
Outcome Measures
Morbidity and Mortality
Postintervention intubation time, days in intensive care
unit (ICU) and hospital length of stay (LOS) were recorded
for all patients undergoing BTT-VAD or HTx. Postinterven-
tion survival was also recorded.
Assessment of Reversibility of Frailty
Follow-up assessments of frailty phenotype, HGS, cognitive
impairment, and depression were conducted postinterven-
tion in patients who were classified as frail preinterven-
tion. All reassessments were performed at least 2 months
postintervention.
Statistical Analysis
Descriptive statistics were calculated for all variables. The
proportion of patients within each category (nonfrail and
frail) was determined for the total study population. Associa-
tion between the frailty category and age, sex, depression,
cognitive impairment, markers of heart failure severity, he-
matological, and biochemical parameters were made using
unpaired t tests or Mann-WhitneyU test for continuous var-
iables and χ2 test for categorical variables. Baseline charac-
teristics are presented as mean ± standard deviation or
median with interquartile range for continuous variables
and frequency (percent) for categorical variables. For com-
parison of outcomes, survival time was defined as the time
between the date of intervention and the date of death or date
of censoring (date of most recent follow-up). Kaplan-Meier
cumulative survival curves were also generated for each
frailty category and the log-rank test was used to compare
survival rates between frail and nonfrail groups. A Coxproportional hazards model was used to assess the associa-
tion between frailty and death adjusting for covariates. To as-
sess changes in frailty, HGS, cognition, and depression at
follow-up, related sample Wilcoxon signed ranked test was
used for continuous data andMcNemar for categorical data.
A P value less than 0.05 was considered statistically signifi-
cant. All the data analyses were conducted using the IBM
SPSS Statistics software (version 24; IBM Corporation).
RESULTS
Frailty Prevalence
During the study period, 100 patients (65 men:35 women;
age 51 ± 13 years; range, 16-71; LVEF, 27 ± 14%) underwent
surgical intervention: 40 VAD implantations (17 of whom
proceeded to HTx) and 60 heart transplants (Figure 1). The
underlying causes of heart failure were dilated cardiomyopa-
thy (58%), ischemic heart disease (22%), hypertrophic or re-
strictive cardiomyopathy (14%), and other cardiac diseases
(6%). Thirty-two patients were identified as physically frail
(32%). Selected baseline demographics by physical frailty
are given in Table 2. Frailty was not associated with age,
BMI, left ventricular end-diastolic dimension or ejection frac-
tion, PAWP and MPAP, cardiac index, blood hemoglobin
level or renal function (as assessed by serum creatinine or
eGFR). Frailty was significantly associated with being fe-
male, NYHA class IV symptomatic status, higher RAP,
higher serum bilirubin and lower serum albumin, as well as
cognitive impairment and depression (both as continuous
and categorical variables). The majority (70%) of frail pa-
tients within the intervention group were younger than
60 years.
Frailty and Postintervention Outcomes
(1) Overall Survival
Postintervention survival for all 100 patients is shown in
Figure 2. For patients who underwent BTT-VAD followed
byHTx, postintervention survivalwas assessed from the time
of VAD implantation. Survival was significantly lower in pa-
tients who were frail before intervention. By 12 months post-
intervention, survival was 94 ± 3% in the nonfrail group
compared with 63 ± 10% in the frail group (P = 0.012,
Cox-Mantel test). Postoperative median ICU and total hospi-
tal LOS were significantly longer in frail patients (11 vs
5 days, P = 0.002 and 49 vs 25 days, P = 0.003, respectively).
We examined the impact of the following variables on
postintervention survival: frailty category (nonfrail vs frail),
age (younger than or older than 60 years), sex, LVEF
(<27% vs ≥ 27%), depression, cognitive impairment, ane-
mia, renal function (eGFR < 60 vs ≥ 60 mL/min per m2), se-
rum albumin (<35 vs or ≥ 35 mmol/L). Applying Cox
proportional hazards model, only frailty and older than
60 years were independent predictors of postintervention
mortality with the hazard ratios of 2.8 (95% confidence in-
terval, 1.1-7.5) and 2.5 (95% confidence interval, 1.0-6.8),
respectively.
(2) Post-VAD Outcomes
Forty patients underwent VAD implantation during this
study, including 6 patients (3 frail and 3 nonfrail) who were
placed on biventricular VAD support. There was a median
of 22 (6-127) days between frailty assessment and VAD
FIGURE 1. Consort diagram illustrating the derivation and outcome of the study population. F frail, NF nonfrail. *2 of 3 BTT-VAD patients were
reclassified as nonfrail before HTx.
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in Table 3. Almost half of all VADpatients (19/40) were iden-
tified as frail; and indeed, there was a significant association
with being frail and proceeding to VAD support (P = 0.022).
Compared with their nonfrail counterparts, frail patients were
intubated for an average of 3 hours longer, spent twice as long
in ICU (median 6 vs 12 days, P < 0.05) and a month longer in
hospital (median 31 vs 57 days, P < 0.05). Fifteen patients died
post-VAD implant. Four of 19 frail patients died postimplantTABLE 2.
Patient demographics by physical frailty
Physical frailty
Total (n = 100)
Age, y 51 ± 13
Sex (male/female) 65:35
BMI, kg/m2 26.1 ± 4.8
Heart failure duration, y 5.0 ± 5.3
LVEDD, mm 67 ± 13
LVEF, % 27 ± 14
HF type: HFrEF:HFpEF 85:15
NYHA class (III:IV) 27:73
RAP, mm Hg 14 ± 7
PAWP, mm Hg 25 ± 8
MPAP, mm Hg 36 ± 10
CI, L/min per m2 1.9 ± 0.5
Se creatinine, μmol/L 111 ± 36
eGFR, L/min per 1.73 m2 61 ± 19
Se bilirubin, μmol/L 26 ± 18
Se albumin, g/L, hypoalbuminemia, n (%) 42 ± 5, 15 (1%)
Hemoglobin, g/L anemia, n (%) 131 ± 18, 36 (36%)
Cognition MOCA score, abnormal MOCA, n (%) 26 ± 4, 36 (36%)
Depression DMI score, abnormal DMI, n (%) 7 ± 6, 34 (34%)
HFrEF, heart failure with a reduced ejection fraction; N, number; ns nonsignificant; Se, serum.and another 3 died posttransplant. Eight of 21 nonfrail pa-
tients died postimplant. Post-VAD deaths tended to occur
earlier in the frail patients: 6 month and 12-month sur-
vival post-VAD implant was lower in frail patients however
the differences were not significant (Table 3). Seventeen
patients proceeded from VAD to HTx: 12 were frail pre-
VAD implantation. Nine of the 12 patients who were frail
pre-VAD underwent frailty reassessment before HTx: all 9
improved their frailty score although 2 were still classifiedNonfrail (n = 68) Frail (n = 32) P
52 ± 12 50 ± 15 ns
50:18 15:17 0.018
26.5 ± 4.6 25.1 ± 5.4 ns
5.1 ± 5.0 4.9 ± 6.2 ns
68 ± 13 66 ± 13 ns
27 ± 13 27 ± 16 ns
58:10 27:5 ns
24:44 3:29 0.012
13 ± 6 17 ± 8 0.020
24 ± 7 27 ± 8 ns
35 ± 9 37 ± 10 ns
1.9 ± 0.6 1.8 ± 0.5 ns
111 ± 33 110 ± 40 ns
62 ± 17 61 ± 22 ns
23 ± 15 31 ± 21 0.047
42 ± 4, 5 (7%) 39 ± 6, 10 (31%) 0.006, 0.005
133 ± 17, 23 (34%) 128 ± 17, 13 (41%) ns, ns
26 ± 3, 18 (26%) 24 ± 4, 18 (56%) 0.024, 0.007
6 ± 5, 18 (26%) 10 ± 8, 16 (50%) 0.002, 0.025
FIGURE 2. Postinterventional survival.
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(at days 16, 44 and 56), 2 from primary graft failure and 1
from infection. All 3 patients had improved their frailty
score post-VAD implant and before HTx although 1 patient
whose score had improved from 5 to 3 was still classified as
frail at the time of transplant. The results of serial frailty
assessments in the 12 patients who were frail pre-VAD and
who proceeded to HTx are illustrated in Figure 3.TABLE 3.
Post-VAD outcomes by physical frailty
Physical frailty
Total (n = 40) Not-Frail (n = 21) Frail (n = 19)
Age, y 55 ± 12 55 ± 11 55 ± 13
Sex (male/female) 31:9 19:2 12:7
LVAD/BiVAD 34:6 18:3 16:3(3) Postheart transplant outcomes
Seventy-seven patients underwent HTx during this study.
There was a median of 183 (98-419) days between frailty as-
sessment and transplantation. Eighteen (23%) patients were
classified as frail before HTx: 5 BTT_VAD patients and
13 patients with AHF not requiring VAD support. Post-
HTx outcomes by frailty status are shown in Table 4. Al-
though nonsignificant, the median duration of intubation
posttransplantationwas 35 hours longer and ICULOS3days
longer for the frail group. Hospital LOS posttransplant was
similar for frail and nonfrail groups. All 6 patients who died
posttransplant had been found to be frail at their initial as-
sessment, although as mentioned above 2 of 3 VAD-
supported patients who died posttransplant had been
reclassified as nonfrail before transplant. Posttransplant sur-
vival at 6 and 12 months was 96 ± 3% in nonfrail patients.
Posttransplant survival for frail patients was 87 ± 8% at
6 months and 66 ± 16% at 12 months. In addition to the 3
VAD-supported patients who died posttransplant, 3 other
patients died: a 57-year-old woman and 21-year-old woman
died at days 104 and 265, respectively, from sepsis/multiorgan
failure and a 29-year-old woman died at day 347 from un-
controllable acute cellular rejection.Intubation, h 24 (21-62) 24 (18-45) 27 (22-93)
ICU post-MCS, d 8 (5-17) 6 (4-10) 12 (7-21)*
LOS post-MCS, d 39 (23-58) 31 (22-45) 57 (28-71)*
Survival at 6 mo, % 80 ± 6 86 ± 8 74 ± 12
Survival at 12 mo, % 71 ± 7 80 ± 9 61 ± 12
Values are mean ± SD for normally distributed continuous data, median (interquartile range) for
nonnormally distributed continuous data, and number for categorical data.
LVAD, left ventricular assist device; BiVAD, both a left and right VAD, MCS, mechanical circulatory
support.
* P < 0.05 Frail versus nonfrail.Reversibility
Frail Preintervention
Of the 32 patients who were identified as frail pre-
intervention, 6 died before reassessment (3 post-VAD and
3 post-HTx). A total of 26 frail patients underwent frailty
reassessment postintervention: 13 post-VAD implantation
and 13 posttransplantation. Follow-up assessments wereperformed 133 (96‐185) days post-VAD and 184 (88‐457)
days post-HTx.
Among the frail pre-VAD patients, there was a significant
improvement in frailty score postintervention (4.0 ± 0.8 to
1.4 ± 1.1, P < 0.001) with 10 of the 13 patients being
recategorized to nonfrail at follow-up (Figure 4A). Of the
3 patients who remained frail postintervention, 2 had an im-
provement in frailty score, although the threshold for
recategorization (<3/5) was not reached. No patients experi-
enced worsening frailty postintervention, although 1 patient
remained unchanged. Ten of the 13 frail pre-VAD patients
had reduced HGS. At reassessment, there was a significant
improvement in grip strength (from 24.5 ± 13.0 kg to
27.6 ± 10.3 kg, P < 0.02), with 3 weak patients being re-
classified to normal grip strength postintervention (Figure 4B).
There was also a nonsignificant improvement in DMI score
(11.5 ± 8.3 vs 5.3 ± 4.3, P = 0.10), with 3 of 5 depressed
patients being recategorized to being not depressed post-
VAD. There was a no change in MOCA score (24.5 ± 4.7 vs
24.5 ± 3.5, P = ns).
Similar trends were seen among those identified as frail
pre-HTx. There was a significant improvement in frailty
score (3.3 ± 0.6 to 0.8 ± 1.0, P < 0.001) with all the frail
patients being recategorized to nonfrail at follow-up
(Figure 5A). Seven of the 13 frail pre-HTx patients had
reduced HGS preintervention. At reassessment, there was a
nonsignificant improvement in grip strength (from 22.9 ±
9.4 to 28.2 ± 10.0 kg, P = 0.114), with 3 of the weak patients
being reclassified to normal grip strength postinterven-
tion (Figure 5B). There was a significant improvement in
DMI score (from 8.9 ± 7.6 vs 3.2 ± 3.5, P = 0.016), with
3 of 5 depressed patients being reclassified as nondepressed
postintervention. Although improved, the change in cogni-
tive impairment at follow-up was nonsignificant (24.3 ± 3.4 vs
27.2 ± 2.4, P = 0.100), with 4 of 6 cognitively impaired patients
being reclassified as normal cognition postintervention.
DISCUSSION
There were 2 major findings of this study. The first is that
patients with documented frailty and AHF have an increased
mortality after major surgical interventions (BTT-VAD or
HTx). There was also increased morbidity, reflected by ex-
tended lengths of stay in the ICU and hospital after these
FIGURE 3. Follow-up frailty among the BTT-VAD/HTx subgroup. Key: solid line with diamond, patients died without post-HTx follow-up, only
post-VAD follow-up (n = 3). Dotted line, patient received a post-HTx follow-up, no post-VAD follow-up (n = 3). Solid line, patients received both
post-VAD and post-HTx follow-up (n = 6). F, female.
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ports of patient groups undergoing major cardiac surgical in-
terventions.11,12 Other authors have reported increased
mortality and duration of hospitalisation after VAD implan-
tation however these studies were performed predominantly
in older destination-VAD recipients.8,13 To our knowledge,
this is the first study to report these findings in a younger
bridge-to-transplant VAD population and in patients under-
going HTx. Despite the increased postprocedural mortality
risk for frail patients compared with their nonfrail counter-
parts, most frail patients survived the intervention: 15 of 19
frail patients undergoing VAD implantation and 13 of 17
frail patients undergoing HTx.
The second major finding was that the frailty phenotype
was partly or completely reversible in the large majority of
patients who could undergo reassessment post-VAD or
posttransplant. Only 1 patient, a 67-year-old man, failed to
improve on his frailty score when repeated 5 months after
VAD implantation. We were concerned that older frail pa-
tients would demonstrate less reversibility than younger pa-
tients. Although the number of patients recruited for thisTABLE 4.
Post-HTx outcomes by physical frailty
Physical frailty
Total (n = 77) Nonfrail (n = 59) Frail (n = 18)
Age, y 50 ± 14 52 ± 13 46 ± 17
Sex (male/female) 47:30 42:18 5:12*
Ischemic time, min 205 ± 94 209 ± 93 188 ± 94
Intubation, h 35 (16‐130) 31 (16‐134) 66 (14‐129)
ICU post-MCS, d 7 (3‐10) 6 (3‐10) 9 (3‐16)
LOS post-MCS, d 25 (16‐46) 25 (15‐39) 25 (18‐57)
Survival at 6 mo, % 94 ± 3 96 ± 3 87 ± 8
Survival at 12 mo, % 90 ± 4 96 ± 3 66 ± 16**
Values are mean ± SD for normally distributed continuous data, median (interquartile range) for non-
normally distributed continuous data, and number for categorical data.
* P < 0.05, frail versus nonfrail.
** P < 0.01, frail versus nonfrail.
MCS mechanical circulatory support.study was too small to discount this possibility, it is notewor-
thy that the oldest patient, a 71-year-old man reversed his
frailty score from 4 to 0 after VAD implant. He subsequently
underwent HTx and remains well 6 months posttransplant.
Based on these findings, we believe that delisting all frail
patients for BTT-VAD or HTx, due to increased procedural
risks, is premature. Although our findings suggest that the
frailty phenotype is wholly or partly reversible in most frail
patients with AHF who undergo BTT-VAD or HTx trans-
plantation, we speculate that reversal of frailty in BTT-VAD
patients reduces the mortality and morbidity risks of subse-
quent HTx however this is also an area where further re-
search is required. It would seem logical that there is a
greater chance of reversal of frailty if related to cardiac fac-
tors rather than noncardiac ones. This raises the question of
whether all items on frailty assessment are equal in their po-
tential reversability.
The reversibility of frailty was initially suggested in the con-
text of patient selection for destination left ventricular assist
device therapy. Flint and colleagues6 hypothesized that the rel-
ative proportion of cardiac- and non–cardiac-related factors
that constitute a patient’s frailty, was indicative of the extent
to which frailty may be reversible postintervention. For in-
stance, if a patient’s frailty was largely the result of cardiac-
related factors, the implant of VAD or HTx, would effectively
ameliorate aspects of their heart failure-induced frailty.
To date, the small number of studies that have measured
frailty pre and postintervention have suggested that this is
the next step in frailty research. One such study by Chung
and colleagues assessed a single item measure of frailty (re-
duced HGS, <25% body weight) monthly for 6 months after
VAD implantation in 72 destination patients. This study
found that HGS significantly improved at 3 months after
VAD implantation and maintained significant improvement
to 6 months. We observed a similar improvement in mean
HGS in our frail cohort; however, this improvement was only
significant for the BTT-VAD group. Comparatively, the im-
provements in total frailty scorewere significant among those
undergoing either BTT-VAD or HTx. This may reflect the
better relative sensitivity of a more comprehensive frailty tool
FIGURE 4. Changes in frailty score and HGS for patient’s frail pre-VAD. F, female; M, male.
© 2017 Wolters Kluwer Jha et al 7for detecting changing frailty status above that of a single-
item measure, such as HGS. Other authors have reported
that gait speed, another single frailty measure, predicts mor-
tality and morbidity after heart surgery and may be more re-
liable than more complex frailty instruments14,15; however,
this measure has limited application in a population with
AHF because many are too sick to mobilize. In addition, to
our knowledge there are no studies that have assessed gait
speed before and after cardiac surgical interventions. Al-
though there is currently limited evidence for reversibility of
frailty within cardiac surgical populations, frailty has been
shown to improve in patients of a similar age undergoing kid-
ney transplantation. This study of 349 patients showed that
although there was an initial worsening of frailty severity
1 month posttransplantation, by 3 months frailty had signif-
icantly improved. Furthermore, patients who were frailFIGURE 5. Changes in frailty score and HGS for patient’s frail pre-HTx.pretransplant were the ones most likely to improve their
frailty score after transplantation.16
The question of cardiac and noncardiac causes is impor-
tant here. If gait speed or hand grip are reduced because of
heart failure-induced weakness, one would expect that they
would improve postintervention, but if they were caused by
some other problem, for example, a neurological condition,
then they may not be reversible. Another important consider-
ation is cognitive function. We have previously reported that
the incorporation of cognitive impairment as an item in
frailty assessment improves the prediction of mortality in pa-
tients with heart failure.4 If the patient has cognitive slowing
due to heart failure-induced apathy or even depression, this
could be potentially reversed but if it is indicative of micro-
vascular disease or hypoxic brain damage, it is unlikely to
be reversible with improved cardiac function.
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To assess the impact of frailty on postoperative survival we
examined the actuarial survival for all 100 patients from the
date of their first intervention: VADorHTx. It is possible that
the impact of frailty on postoperative mortality may differ
per the type of surgical intervention, however given the im-
pact of frailty on outcomes after other major cardiac surgical
procedures we believe that the adverse effect of frailty on op-
erativemortality is likely to be similar for VADandHTx. An-
other limitation of our study was the variable time between
baseline frailty assessment and the surgical intervention. This
was explained in part by the fact that patients underwent
frailty assessment at the time of initial referral which did
not necessarily coincide with the timing of BTT-VAD or
HTx. There was also considerable variation in the timing
of repeat frailty assessment postintervention. However, all
patients were at least 2 months postintervention to allow
adequate time for recovery from the surgical procedure.
Regardless of the timing of postintervention frailty assess-
ment, it does not affect the interpretation of our critical
finding that the frailty phenotype is substantially reversible
in most patients.
Decisions regarding themanagement of patientswith AHF
need to take into consideration the increased morbidity and
mortality risks associated with frailty and the prospects of
reversing frailty after the intervention. We initially hypo-
thesized that frailty would be more prevalent and less re-
versible in older patients with AHF but so far have found
this not to be the case.3,4 We believe that future studies should
focus on identification of measures to distinguish reversible
from irreversible frailty and on the role of prehabilitation to
see if frailty can be reversed at least in part before BTT-
VAD or HTx.17-19CONCLUSION
Frail patients with AHF experience increased mortality
after surgical intervention with BTT-VAD or HTx. Frail pa-
tients also experience increased morbidity after these proce-
dures as reflected by longer ICU and hospital stays; however,
for those who survive, the perioperative period frailty is
partly or completely reversible in themajority. Based on these
data, measurement andmonitoring frailty status is an impor-
tant tool in planning clinical care.REFERENCES
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